ArticleRetina (Philadelphia, Pa.)2018
CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6-The MacTel Research Group.
Article in Retina (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Beyond Performance Metrics: Automatic Deep Learning Retinal OCT Analysis Reproduces Clinical Trial Outcome.Ophthalmology · 2020Trial
- Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.Ophthalmology · 2019Trial
- Prevalence and Visual Acuity Characteristics of Patients with Macular Telangiectasia.Ophthalmology and therapy · 2026Article
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Does macular telangiectasia type 2 influence the retinal microvasculature in diabetic retinopathy?Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Longitudinal spatial correlation of retinal sensitivity and structural changes in macular telangiectasia type 2.International journal of retina and vitreous · 2026Article
- Ethnic comparison of MacTel over 5 years follow up.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Observational
- Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options.Journal of clinical medicine · 2026Review
- Optical Coherence Tomography Angiography Characterization of Vascular Alterations in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2026Observational
- Validation of Macular Telangiectasia Type-2 (MacTel) multimodal imaging-based classification system in a cohort from India.Eye (London, England) · 2026Article
- Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2.Ophthalmology science · 2026Article
- Morphological, vascular, and functional changes in macular telangiectasia type 2 in Egyptian patients.Scientific reports · 2025Article
- Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2.The British journal of ophthalmology · 2025Article
- Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025Review
- Prognostic Relevance of Relative Ellipsoid Zone Reflectivity for Ellipsoid Zone Loss in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2024Observational
- Quantification of vascular changes in macular telangiectasia type 2 with AngioTool software.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Skeleton density and ellipsoid zone loss are prognostic for progression in Macular Telangiectasia Type 2.Scientific reports · 2024Article
- Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.International journal of retina and vitreous · 2023Review
- Longitudinal anatomical and visual outcome of macular telangiectasia type 2 in Asian patients.Scientific reports · 2023Article
- Relation of interdigitation zone changes and right-angle vessels in Macular Telangiectasia Type-2 (MacTel).Eye (London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo evaluate progression of macular telangiectasia Type 2 lesions and their correlation with visual acuity.
methodsAn international multicenter prospective study with annual examinations including best-corrected visual acuity (BCVA), fundus photography, fluorescein angiography, and optical coherence tomography images graded centrally. Mixed models were used to estimate progression rates, and a generalized linear model to compute the relative risk of BCVA loss, loss of ellipsoid zone (EZ) reflectivity, development of pigment plaques, or neovascularization.
resultsOne thousand and fourteen eyes of 507 participants were followed for 4.2 ± 1.6 years. Best-corrected visual acuity decreased 1.07 ± 0.05 letters (mean ± SE) per year. Of all eyes, 15% lost ≥15 letters after 5 years. Of the eyes without EZ loss, 76% developed a noncentral loss. Of the eyes with noncentral loss, 45% progressed to central EZ loss. The rate of BCVA loss in eyes with noncentral EZ loss at baseline was similar to eyes without EZ loss. The rate of BCVA loss was significantly higher in eyes with central EZ loss at baseline (-1.40 ± 0.14 letters, P < 0.001).
conclusionEllipsoid zone loss is frequently found in macular telangiectasia Type 2 and is an important structural component reflecting visual function. Its presence in the fovea significantly correlates with worse visual prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.